PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects.

Rincón, Raúl

PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects. [electronic resource] - Oncotarget Feb 2015 - 4299-314 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1949-2553

10.18632/oncotarget.3012 doi


Adult
Aged
Aged, 80 and over
Animals
Antibiotics, Antineoplastic--pharmacology
Biomarkers, Tumor--analysis
Blotting, Western
Breast Neoplasms--drug therapy
Doxorubicin--pharmacology
Drug Resistance, Neoplasm--physiology
Enzyme Activation--physiology
Female
Humans
Immunohistochemistry
Kaplan-Meier Estimate
Mice
Mice, Inbred BALB C
Middle Aged
Prognosis
Protein Phosphatase 2--metabolism
Real-Time Polymerase Chain Reaction
Treatment Outcome